Suzhou Basecare Medical Corp. Ltd. Class H (HK:2170)
:2170
Want to see HK:2170 full AI Analyst Report?
Top Page
Suzhou Basecare Medical Corp. Ltd. Class H
(2170)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$1.50
▼(-23.86% Downside)
Action:Reiterated
Date:05/16/26
The score is primarily weighed down by weak financial performance driven by large ongoing losses and persistent cash burn, alongside a pronounced technical downtrend with negative momentum. Valuation inputs provided do not add supportive evidence (P/E shown as 0.000 and no dividend yield).
Positive Factors
Recurring consumables revenue
The company derives recurring revenue from consumables used per ART procedure, creating predictable, repeatable demand tied to clinic volumes. This installed-base driven model supports long-term revenue visibility, customer stickiness, and steady unit sales even if device purchases fluctuate.
Negative Factors
Persistent operating losses
Very large operating and net losses signal the core business is not covering operating costs. Sustained negative EBIT margins near -88% mean profitability depends on substantial margin expansion or cost cuts; without that, losses will continue to erode equity and hinder strategic options.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables revenue
The company derives recurring revenue from consumables used per ART procedure, creating predictable, repeatable demand tied to clinic volumes. This installed-base driven model supports long-term revenue visibility, customer stickiness, and steady unit sales even if device purchases fluctuate.
Read all positive factors
Suzhou Basecare Medical Corp. Ltd. Class H (2170) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$380.20M
Dividend YieldN/A
Average Volume (3M)121.73K
Price to Earnings (P/E)―
Beta (1Y)1.36
Revenue Growth-21.90%
EPS Growth5.78%
CountryHK
Employees497
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.86
Shares Outstanding82,713,840
10 Day Avg. Volume98,950
30 Day Avg. Volume121,733
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)0.49
Price to Sales (P/S)1.96
P/FCF Ratio-1.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.23
Revenue Forecast (FY)HK$412.00M
Suzhou Basecare Medical Corp. Ltd. Class H Business Overview & Revenue Model
Company Description
Suzhou Basecare Medical Corporation Limited, an investment holding company established in Suzhou, China, in 2010, focuses its business activities within the People's Republic of China. The company primarily engages in the research, development, an...
How the Company Makes Money
The company makes money primarily by selling ART medical devices and consumables to hospitals, fertility clinics, and IVF laboratories. Its revenue model is product-based: (1) recurring revenue from consumables used per procedure and routine lab o...
Suzhou Basecare Medical Corp. Ltd. Class H Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 275.71M | 233.27M | 299.11M | 207.98M | 140.90M | 107.30M |
| Gross Profit | 131.54M | 123.61M | 136.22M | 91.35M | 59.53M | 51.15M |
| EBITDA | -226.62M | -166.99M | -253.30M | -174.14M | -117.73M | -118.88M |
| Net Income | -238.59M | -223.46M | -237.03M | -191.69M | -123.16M | -143.65M |
Balance Sheet | ||||||
| Total Assets | 1.57B | 1.45B | 1.67B | 1.90B | 1.78B | 1.80B |
| Cash, Cash Equivalents and Short-Term Investments | 545.48M | 447.34M | 684.63M | 945.71M | 1.33B | 1.52B |
| Total Debt | 342.23M | 343.51M | 328.42M | 281.92M | 75.54M | 48.57M |
| Total Liabilities | 535.35M | 512.00M | 527.47M | 499.98M | 188.33M | 85.85M |
| Stockholders Equity | 1.03B | 935.06M | 1.14B | 1.40B | 1.59B | 1.72B |
Cash Flow | ||||||
| Free Cash Flow | -297.35M | -243.37M | -322.41M | -371.44M | -317.52M | -234.71M |
| Operating Cash Flow | -207.59M | -160.01M | -229.12M | -267.23M | -188.77M | -197.85M |
| Investing Cash Flow | -1.63M | -5.33M | -181.19M | -324.81M | -88.70M | -56.60M |
| Financing Cash Flow | -10.49M | 16.13M | 33.78M | 190.55M | 23.51M | 1.60B |
Suzhou Basecare Medical Corp. Ltd. Class H Technical Analysis
Negative
1.97
Price Trends
1.71
Negative
1.82
Negative
2.22
Negative
Market Momentum
-0.09
Negative
32.53
Neutral
72.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2170, the sentiment is Negative. The current price of 1.97 is above the 20-day moving average (MA) of 1.43, above the 50-day MA of 1.71, and below the 200-day MA of 2.22, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 32.53 is Neutral, neither overbought nor oversold. The STOCH value of 72.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2170.
Suzhou Basecare Medical Corp. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Neutral | HK$6.10B | 15.45 | 12.01% | 1.26% | 10.19% | 23.70% | |
61 Neutral | HK$6.52B | 41.10 | 4.06% | ― | 5.10% | -32.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$12.67B | 28.57 | 6.07% | ― | -3.62% | ― | |
42 Neutral | HK$380.20M | -1.47 | -21.57% | ― | -21.90% | 5.78% | |
42 Neutral | HK$582.14M | -1.22 | -21.29% | ― | -34.96% | 42.74% | |
41 Neutral | HK$1.53B | -0.81 | -7.01% | ― | -4.38% | ― |
* Healthcare Sector Average
HK:2170
Suzhou Basecare Medical Corp. Ltd. Class H
1.39
-1.50
-51.90%
HK:0853
MicroPort Scientific
6.61
-1.21
-15.47%
HK:1302
LifeTech Scientific Corporation
1.51
-0.53
-25.98%
HK:1789
AK Medical Holdings Ltd.
5.43
-0.44
-7.50%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.20
-3.15
-72.41%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
1.32
-1.25
-48.64%
Suzhou Basecare Medical Corp. Ltd. Class H Corporate Events
Suzhou Basecare Shareholders Approve All Resolutions at 2025 AGM
Jun 4, 2026
Suzhou Basecare Medical Corporation Limited, a PRC-incorporated medical company listed on the Hong Kong Stock Exchange, operates through a group structure and relies on international auditing standards. The company is overseen by a board of direct...
Suzhou Basecare Wins NMPA Approval, Completes Certification of Gems IVF Reagent Line
May 29, 2026
Suzhou Basecare Medical Corporation Limited has secured NMPA approval in China for its Class III medical device registration certificate covering the Gems series egg retrieval solution, a core reagent used at the outset of IVF procedures. The solu...
Basecare Wins NMPA Class III Approval for Gems Embryo Culture Medium
May 13, 2026
Suzhou Basecare Medical Corporation Limited has obtained National Medical Products Administration approval in China for its independently developed Gems cleavage embryo culture medium as a Class III medical device. The product had already secured ...
Suzhou Basecare Calls 2025 AGM to Approve Reports, Budget and Capital Mandates
May 12, 2026
Suzhou Basecare Medical Corporation Limited has called its 2025 annual general meeting for June 4, 2026, in Suzhou, where shareholders will review key 2025 corporate reports, including board and supervisory reports, the annual report, and the grou...
Suzhou Basecare to Convert 190 Million Unlisted Shares into H Shares for Full Circulation
May 12, 2026
Suzhou Basecare Medical Corporation Limited plans to implement an H share full circulation scheme by converting 190,812,165 domestic unlisted shares into H shares tradable on the Hong Kong Stock Exchange. The move, which does not require further s...
Basecare to Amend Articles and Cancels Planned Class Meetings
May 12, 2026
Suzhou Basecare Medical Corporation Limited plans to amend its articles of association to align with updated Hong Kong listing rules and relevant regulations, aiming to strengthen corporate governance and operational compliance. Key changes includ...
Basecare Wins First China Approval for Thalassemia-Focused PGT-M Kit, Strengthening IVF Genetics Lead
Apr 29, 2026
Suzhou Basecare Medical Corporation Limited has received national Class III medical device registration from Chinese regulators for its independently developed Pre-implantation Genetic Testing Kit for Thalassemia, becoming the first such thalassem...
Suzhou Basecare Wins NMPA Approval for Key IVF Media, Bolstering Assisted Reproduction Portfolio
Apr 7, 2026
Suzhou Basecare Medical Corporation Limited has received Class III medical device registration certificates from China’s National Medical Products Administration for its fertilisation medium and blastocyst medium, two core products in its Ge...
Basecare pivots to commercialization as revenue dips but margins improve in 2025
Mar 30, 2026
Suzhou Basecare Medical Corporation Limited reported 2025 revenue of RMB233.3 million, down from RMB299.1 million in 2024, while narrowing its operating loss and improving gross margins through cost controls and a refined product and regional mix....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.